Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

60 Degrees Pharmaceuticals (SXTP) Return on Invested Capital (2023 - 2025)

60 Degrees Pharmaceuticals (SXTP) has disclosed Return on Invested Capital for 3 consecutive years, with 0.48% as the latest value for Q1 2025.

  • On a quarterly basis, Return on Invested Capital rose 27.0% to 0.48% in Q1 2025 year-over-year; TTM through Mar 2025 was 0.48%, a 27.0% increase, with the full-year FY2024 number at 0.28%, down 92.0% from a year prior.
  • Return on Invested Capital was 0.48% for Q1 2025 at 60 Degrees Pharmaceuticals, down from 0.3% in the prior quarter.
  • In the past five years, Return on Invested Capital ranged from a high of 0.57% in Q3 2023 to a low of 1.89% in Q3 2024.
  • A 3-year average of 0.62% and a median of 0.57% in 2025 define the central range for Return on Invested Capital.
  • Biggest YoY gain for Return on Invested Capital was 36bps in 2024; the steepest drop was -245bps in 2024.
  • 60 Degrees Pharmaceuticals' Return on Invested Capital stood at 0.65% in 2023, then surged by 55bps to 0.3% in 2024, then plummeted by -62bps to 0.48% in 2025.
  • Per Business Quant, the three most recent readings for SXTP's Return on Invested Capital are 0.48% (Q1 2025), 0.3% (Q4 2024), and 1.89% (Q3 2024).